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ORIGINAL ARTICLE
ABSTRACT
Aim: to distinguish the expression of NF-κΒ and COX-2
between young and older group of sporadic colorectal
cancer patients.
Methods: this was a comparative study between
sporadic CRC patients aged 40 years or younger and
patients aged 60 years or more. Expression of NF-κΒ and
COX-2 were assessed by immunohistochemical method
using rabbit polyclonal antibodies against human p65 NF-
κΒ and COX-2 proteins.
Results: there were 98 cases of sporadic colorectal
cancers between 1999 and 2007 obtained from the
Department of Anatomical Pathology, Faculty of Medicine
University of Indonesia, Jakarta and Department of
Anatomical Pathology, Faculty of Medicine Padjajaran
University, Bandung. There were 60 patients aged 60 years
or more and 38 patients aged 40 years or less. Most tumors
were located in the distal colon. Positive expression of NF-
κΒ was found in 72 (73.5%) cases, whereas COX-2
expression was found in 48 (49.0%) cases. No significant
difference of NF-κΒ and COX-2 expression between young
and older patients.
Conclusion: the expression of nuclear factor κΒ
(NF-κΒ) in Indonesian patients with sporadic colorectal
cancer was high. However, cyclooxygenase-2 (COX-2) was
only expressed in half of patients. There was no significant
difference of NF-κΒ and COX-2 expressions between patients
aged 40 years or less and patients aged 60 years or more.
Further studies are needed to elaborate the role of
inflammation in sporadic colorectal carcinogenesis.
Key words: sporadic colorectal cancer, young patient,
inflammation, NF-κΒ, COX-2.
INTRODUCTION
The prevalence of colorectal cancer (CRC) in
Western population aged 50 years or less was 2-8%.1,2
However, epidemiological data in Indonesia has shown
that the proportion of CRC patients aged 40 years or
less was higher (more than 30%).3 Furthermore, studies
in developed countries found that young onset CRC
often associated with a positive family history.4,5 The
pathogenesis of familial or hereditary CRC involved
germ-line mutations of the so-called mismatch repair
(MMR) genes and was named microsatellite instability
pathway.6 In contrast, sporadic CRC follow chromosomal
instability (CIN) pathway7 that involved somatic
mutation in adenomatous poliposis coli (APC) gene and
other mutations which has been described as adenoma-
carcinoma sequence.8 Previous study in Indonesian
young CRC patients did not find any positive family
history and the expression of MMR proteins did not
differ from older patients.9 It seems that colorectal
carcinogenesis of young patients did not differ from
elder patients and might follow a sporadic pathway.
Several clinical studies in the last two decades has
shown that non-steroidal anti-inflammatory steroids, i.e.
sulindac and cyclooxygenase-2 (COX-2) inhibitor,
reduced the number and the size of adenomatous
polyps.10,11 Further studies has focused in the role of
COX-2 enzymes in the formation of colorectal adenoma.
COX-2 expression was regulated by Wnt/APC/β-catenin
pathway which is a CIN pathway. In cells with normal
APC, the expression of COX-2 was reduced at the
translational level.12 Additionally, COX-2 enzyme was
not expressed in 61% of CRC patients with high MSI or
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negative expression of MMR proteins.13 COX-2 enzyme
is induced by epithelial injury as part of inflammatory
response to infections or other stimuli.14,15 Cell injury
induces the synthesis of prostaglandins which require
COX enzymes. COX-2 has a role in early inflammation
and also in tissue recovery and could be undetectable in
normal tissue.16
Mutations in sporadic cancers are believed to occur
in somatic cells following exposure to environmental
carcinogenic agents. One of conditions that could
provide microenvironmental milieu to induce malignant
transformation of epithelial cells is chronic
inflammation.17 Inflammatory-induced carcinogenesis
pathway involved a transcription factor called nuclear
factor-kappa B (NF-κΒ)18 which is an important
mediator of the growth and development of
inflammatory-induced tumorigenesis. 19
Immunohistochemical staining of COX-2 expression
has been associated with other inflammatory markers,
such as interleukin (IL)-1β, IL-6 and subunit p65
NF-κΒ both in the epithelial or stromal cells.20 This
suggested that inflammatory process play roles in
sporadic colorectal carcinogenesis although the exact
mechanism is not clear and might involved dysplastic
epithelial cells rather than adenoma.21
Molecular studies of inflammatory markers in young
patients with CRC in Indonesia are limited. In particular,
there is no study assessing the role of NF-κΒ and COX-
2 in young CRC patients. This study was aimed to
explore the expression pattern NF-κΒ and COX-2 in
Indonesian patients and to distinguish their expressions
between young and older group of patients.
METHODS
Study Design and Subjects
The study was a comparison study between
colorectal cancer patients aged 40 years or less and
patients aged 60 years or more. Cases were selected
from medical record in the Department of Anatomical
Pathology in Cipto Mangunkusumo and Hasan Sadikin
Hospitals between January 1998 and April 2008. Only
cases with sufficient paraffin tissue materials were
enrolled in this study.
Tissue Specimens and Preparation
Tissue specimens were taken at operation for
histopathological confirmation of colorectal cancer and
then were fixed in 4% buffered formaldehyde and
embedded in paraffin wax. Four ìm sections were cut
and rinsed with cold water. Sections then were placed
onto glass slides and put in warm water (50oC). Next,
slides were placed in a hot plate (70oC) for 15 minutes
and then were incubated over night at 35-40oC.
Immunohistochemical Staining of NF-κB and COX-2
The expression of NF-κΒ and COX-2 was
evaluated using the avidin/biotin complex immunohis-
tochemistry procedure. Rabbit polyclonal antibodies
against human COX-2 protein (Cat No.#ab15191,
Abcam, UK) and human NF-κΒ p65 subunit (RelA)
(Cat No.#ab7970, Abcam, UK) were employed as
primary antibodies.
Tissue sections were sequentially deparaffinized and
rehydrated through xylene and graded alcohol solutions.
Afterward, slides were pre-treated with epitope retrieval
system and were pre-heated in a microwave for 5
minutes. Sections then were immersed in phosphate
buffer saline (PBS) for 5 minutes. Blocking of
endogenous peroxidase activity was done by immersing
the sections into a solution of 3% hydrogen peroxide plus
methanol (1:9) for 10 minutes in refrigerator, and then
were rinsed with PBS for 5 minutes. Slides were marked
by a Pap pen and then put again in PBS. Next, slides
were removed from PBS and were placed in a
treatment chamber. Blocking solution was applied into
each sections and the chamber was closed for 10
minutes.
Primary antibodies were diluted in distilled water with
1:100 for COX-2 and 1:150 for NF-κΒ. Sections were
then incubated with primary antibody in the treatment
chamber for 45 minutes. After washing with PBS,
antibody binding was detected by incubation with
bitinylated secondary antibody for 10 minutes. Then the
slides were washed again with PBS and incubated with
straptavidin-horse radish peroxydase. Staining was
developed by applying the chromogen 3,3
diaminobenzidine in distilled water and then counterstain
with hematoxylin. Finally, specimens were dehydrated
and mounted. Positive and internal negative controls were
included in each staining. Internal negative control
sections run without the addition of primary antibodies.
Positive control was fibroblast cells known to have
positive COX-2 expression.
Slide Readings
Intensity of staining was divided into 4 groups: 0: no
staining; 1: weak staining, 2: moderate staining, 3: strong
staining. Percentage counts of stained cells were scored
as 0 (0%), 1 (<25%), 2 (26-50%), 3 (51-75%), and 4
(76-100). The final score were the sum of intensity and
percentage counts scores, which were between 0 and
7. Tumors having a final score 3 or more were
considered positive. All immunohistochemically stained
slides were reviewed by two pathologists blinded from
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clinical data (kappa values were 0.831 for NF-κΒ
staining and 0.898 for COX-2 staining).
Data Management and Analysis
Patients’ characteristics and all variables were
presented descriptively. Difference between groups was
tested by using Chi-square test or Fisher’s exact test. A
p value of < 0.05 was considered significant. Analysis
was done using the STATA version 9.0 software (STATA
Corporation, TX, USA).
RESULTS
There were 108 cases of sporadic colorectal
cancers between 1999 and 2007. Paraffin block archives
could be obtained in 98 patients and they were enrolled
in this study. Specimens were obtained from the
Department of Anatomical Pathology, Faculty of
Medicine University of Indonesia, Jakarta and
Department of Anatomical Pathology, Faculty of
Medicine Padjajaran University, Bandung.
Most patients were women with a ratio of 1.4:1
compare to men. There were 60 patients aged 60 years
or more and 38 patients aged 40 years or less. The
youngest patient was 14 years old and the oldest was 89
years old. Most tumors were located in the distal colon.
There was no significant difference between both groups
of patients in terms of sex, tumor location, clinical stage,
histopathological type and grade. (Table 1)
Positive expression of NF-κΒ was found in 72
(73.5%) cases, whereas COX-2 expression was found
in 48 (49.0%) cases. There was no significant
difference of NF-κΒ in both groups of patients. COX-2
expression tended to be higher in patients aged 40 years
or less, but the difference was not statistically
significant. (Table 2)
DISCUSSION
Our current study did not show a significant
difference of NF-κΒ expression between young and older
patients. In both groups, the expression of NF-κΒ was
very high (73%). Study in Wuhan, China also did not
find a significant difference of RelA, a component of
NF-κΒ, between CRC patients aged 55 years or less
and patients aged more than 55 years. Both groups
showed RelA expression more than 85%.22
The expression COX-2 in our study also did not
differ between young and older patients. This result is
quite similar with a study in Korea which found positive
COX-2 expression in 46.2% of patients aged less than
60 years and 39.4% of patients aged 60 years or more.23
The expression of COX-2 expression in young
onset sporadic CRC was only sparsely studied in
Western countries. COX-2 expression was not usually
associated to young age, but to the presence of
microsatellite instability (MSI). A study reported that MSI
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was more frequently found in patients aged 40 years or
less compared to patients aged 41-60 years (18.3% vs.
6.6%; p<0.0001).24 Previous study in Indonesian patients
found that expression of MMR proteins did not differ
between young and older patients. The study evaluated
two kinds of MMR proteins, namely MSH-2 and MLH-
1. In both groups of patients, the expression of MSH-2
was not expressed in about 40% patients whereas MLH-
1 was not expressed in more than 83% patients.25 This
result could be a potential explanation to the low
expression of COX-2 in our current study.
Figure 1. Immunohistochemical staining of NF-êB in colorectal
cancer specimens (magnification x400)
Figure 2. Immunohistochemical staining of COX-2 in colorectal
cancer specimens (magnification x400)
CONCLUSION
The expression of nuclear factor κΒ (NF-κΒ) in
Indonesian patients with sporadic colorectal cancer was
high. However, cyclooxygenase-2 (COX-2) was
expressed in only about half of patients. Though there
was no significant difference of NF-κΒ and COX-2
expressions between patients aged 40 years or less and
patients aged 60 years or more statistically, however the
expression of COX-2 tend to increase among younger
age. Further studies are needed to elaborate the role of
inflammation in sporadic colorectal carcinogenesis.
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